Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study - Takeaways - MDSpire

Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study

  • By

  • Benita Salomon

  • Padhmanand Sudhakar

  • Daniel Bergemalm

  • Erik Andersson

  • Olle Grännö

  • Marie Carlson

  • Charlotte R H Hedin

  • Johan D Söderholm

  • Lena Öhman

  • the COLLIBRI Consortium the BIO IBD Consortium

  • Ryan C Ungaro

  • Konrad Aden

  • Geert D’Haens

  • Mark S Silverberg

  • Sven Almer

  • Francesca Bresso

  • Adam Carstens

  • Mauro D’Amato

  • Carl Eriksson

  • Henrik Hjortswang

  • Åsa V Keita

  • Maria Ling Lundström

  • Maria K Magnusson

  • Jóhann P Hreinsson

  • Hans Strid

  • Carl Mårten Lindqvist

  • Robert Kruse

  • Dirk Repsilber

  • Bram Verstockt

  • Séverine Vermeire

  • Jonas Halfvarson

  • November 4, 2024

  • 0 min

Share

  • 1

    The study analyzed inflammatory serum proteins to characterize the heterogeneity of inflammatory bowel disease (IBD) across multiple European cohorts.

  • 2

    A total of 86 inflammation-related serum proteins were measured in 1551 IBD patients and 312 healthy controls using proximity extension methodology.

  • 3

    Significant differences in protein levels were found between IBD subtypes, particularly between ileal and colonic IBD.

  • 4

    Classification models demonstrated better accuracy in differentiating ulcerative colitis from ileal Crohn's disease compared to colonic Crohn's disease.

  • 5

    The findings support a continuous spectrum of IBD, suggesting colonic Crohn's disease resembles ulcerative colitis more than ileal Crohn's disease.

Original Source(s)

Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study

  • by Benita Salomon, Padhmanand Sudhakar, Daniel Bergemalm, Erik Andersson, Olle Grännö, Marie Carlson, Charlotte R H Hedin, Johan D Söderholm, Lena Öhman, the COLLIBRI Consortium the BIO IBD Consortium, Ryan C Ungaro, Konrad Aden, Geert D’Haens, Mark S Silverberg, Sven Almer, Francesca Bresso, Adam Carstens, Mauro D’Amato, Carl Eriksson, Henrik Hjortswang, Åsa V Keita, Maria Ling Lundström, Maria K Magnusson, Jóhann P Hreinsson, Hans Strid, Carl Mårten Lindqvist, Robert Kruse, Dirk Repsilber, Bram Verstockt, Séverine Vermeire, Jonas Halfvarson

  • November 4, 2024

Related Content

Pregnane X receptor (NR1I2) deficiency in mice reveals context-dependent regulation of inflammatory homeostasis

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Link Between Blastocystis Subtypes 3 and 4 and Intestinal Inflammation as Well as Metronidazole Efficacy in Symptomatic Individuals